DE60043346D1 - Methoden zur hemmung der aktivität der osteoklasten - Google Patents

Methoden zur hemmung der aktivität der osteoklasten

Info

Publication number
DE60043346D1
DE60043346D1 DE60043346T DE60043346T DE60043346D1 DE 60043346 D1 DE60043346 D1 DE 60043346D1 DE 60043346 T DE60043346 T DE 60043346T DE 60043346 T DE60043346 T DE 60043346T DE 60043346 D1 DE60043346 D1 DE 60043346D1
Authority
DE
Germany
Prior art keywords
methods
trance
disclosed
activity
amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60043346T
Other languages
German (de)
English (en)
Inventor
Ramachandran Murali
Mark I Greene
Masahiko Kinosaki
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Pennsylvania Penn
Original Assignee
University of Pennsylvania Penn
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Pennsylvania Penn filed Critical University of Pennsylvania Penn
Application granted granted Critical
Publication of DE60043346D1 publication Critical patent/DE60043346D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/02—Halogenated hydrocarbons
    • A61K31/025—Halogenated hydrocarbons carbocyclic
    • A61K31/03—Halogenated hydrocarbons carbocyclic aromatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1013—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1021—Tetrapeptides with the first amino acid being acidic

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Pain & Pain Management (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE60043346T 1999-07-28 2000-07-28 Methoden zur hemmung der aktivität der osteoklasten Expired - Lifetime DE60043346D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14609499P 1999-07-28 1999-07-28
PCT/US2000/020502 WO2001008677A1 (en) 1999-07-28 2000-07-28 Methods of inhibiting osteoclast activity

Publications (1)

Publication Number Publication Date
DE60043346D1 true DE60043346D1 (de) 2009-12-31

Family

ID=22515834

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60043346T Expired - Lifetime DE60043346D1 (de) 1999-07-28 2000-07-28 Methoden zur hemmung der aktivität der osteoklasten

Country Status (7)

Country Link
EP (1) EP1207873B1 (https=)
JP (1) JP4790179B2 (https=)
AT (1) ATE448781T1 (https=)
AU (2) AU778190B2 (https=)
CA (2) CA2380007A1 (https=)
DE (1) DE60043346D1 (https=)
WO (1) WO2001008677A1 (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU777634B2 (en) * 1999-07-28 2004-10-28 Kazuhiro Aoki Methods of inhibiting osteoclastogenesis
WO2002024896A2 (en) 2000-09-22 2002-03-28 Immunex Corporation Screening assays for agonists or antagonists of receptor activat or of nf-kb
ATE399790T1 (de) 2001-07-03 2008-07-15 Febit Biotech Gmbh Zweistufige schutzgruppen für die synthese von biopolymeren
KR101560844B1 (ko) * 2007-06-04 2015-10-15 벤-구리온 유니버시티 오브 더 네게브 리서치 앤드 디벨럽먼트 어쏘러티 트라이-아릴계 화합물 및 이를 포함하는 조성물
US20100260680A1 (en) * 2007-06-05 2010-10-14 Oriental Yeast Co., Ltd. Novel bone mass increasing agent
RU2010150688A (ru) * 2008-05-13 2012-06-20 Ашок Ранганат ШЕЛАР (IN) Медицинские применения гидразонов бензойной кислоты, синтезированных на основе стероидного тигогенина
WO2013035852A1 (ja) 2011-09-09 2013-03-14 住友電気工業株式会社 給電システム及び接続コネクタ
WO2014062625A1 (en) * 2012-10-15 2014-04-24 Iowa State University Research Foundation, Inc. Tackifier compounds and methods of using the same
CN105209427B (zh) * 2013-03-15 2018-05-25 特罗菲克斯制药股份有限公司 非肽bdnf神经营养蛋白模拟物
CN105189449A (zh) 2013-03-15 2015-12-23 特罗菲克斯制药股份有限公司 非肽bdnf神经营养蛋白模拟物
US9321803B2 (en) * 2013-07-12 2016-04-26 Children's Hospital Medical Center Compositions and methods for inhibiting norovirus infection
MX2016005995A (es) 2013-11-05 2016-08-17 Ben-Gurion Univ Of The Negev Res And Dev Authority Compuestos para el tratamiento de diabetes y complicaciones de la enfermedad derivadas de la misma.
US10077257B2 (en) 2015-04-06 2018-09-18 Iowa State University Research Foundation, Inc. Aziridinated triglycerides and polymers formed therefrom
US10392471B2 (en) 2015-05-14 2019-08-27 Iowa State University Research Foundation, Inc. Polymers and methods of making the same
EP3299382B1 (en) * 2015-05-20 2023-04-26 Osaka University Oligopeptide having proinflammatory cytokine secretion-inhibiting activity
EP3600397A4 (en) 2017-03-28 2021-01-27 Children's Hospital Medical Center NOROVIRUS PARTICLE VACCINES AND THEIR MANUFACTURING AND USE PROCEDURES
CN110229118B (zh) 2019-06-28 2021-03-02 深圳市三启药物开发有限公司 腙酰胺类衍生物及其在制备抗骨质疏松药物中的应用
CN111686116B (zh) * 2020-06-08 2021-05-04 广东省微生物研究所（广东省微生物分析检测中心） 孕甾烷衍生物在制备破骨细胞分化抑制剂中的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69740107D1 (de) * 1996-12-23 2011-03-10 Immunex Corp Rezeptor aktivator von nf-kappa b, rezeptor is mitglied der tnf rezeptor superfamilie
AU762574B2 (en) * 1998-05-14 2003-06-26 Immunex Corporation Method of inhibiting osteoclast activity
WO2000001349A2 (en) * 1998-07-01 2000-01-13 The Trustees Of The University Of Pennsylvania Cavity induced allosteric modification of intermolecular interactions and methods of identifying compounds that effect the same
HUP0103578A3 (en) * 1998-09-15 2005-11-28 Pharmexa As Method for down-regulating osteoprotegerin ligand activity
AU777634B2 (en) * 1999-07-28 2004-10-28 Kazuhiro Aoki Methods of inhibiting osteoclastogenesis

Also Published As

Publication number Publication date
AU6384600A (en) 2001-02-19
JP2003505503A (ja) 2003-02-12
CA2380007A1 (en) 2001-02-08
WO2001008677A1 (en) 2001-02-08
EP1207873B1 (en) 2009-11-18
AU778190B2 (en) 2004-11-18
ATE448781T1 (de) 2009-12-15
WO2001008677A8 (en) 2001-07-12
AU2005200650B2 (en) 2007-11-15
AU2005200650A1 (en) 2005-03-10
JP4790179B2 (ja) 2011-10-12
CA2647796A1 (en) 2001-02-08
EP1207873A4 (en) 2006-04-12
EP1207873A1 (en) 2002-05-29

Similar Documents

Publication Publication Date Title
DE60043346D1 (de) Methoden zur hemmung der aktivität der osteoklasten
DE60316779D1 (de) Thiadiazolylpiperazinderivate geeignet für die behandlung bzw. prävention von schmerzen
HUP0100437A2 (hu) Szabályzott felszabadulású gyógyszerkészítmény tolterodin adagolására
WO2009129509A3 (en) Methods and compositions for treating post-operative pain comprising a local anesthetic
ATE387912T1 (de) Transepikutane darreichungsform zur behandlung des restless leg syndroms
NO20101190L (no) Anvendelse av buprenorfin i fremstillingen av et medikament
DE60041147D1 (de) Pharmazeutische zusammenstellungen und zubereitungen zur behandlung von stoffwechselbedingten knochenerkrankungen
WO2004110302A3 (en) Methods of delivering anti-restenotic agents from a stent
DE60324427D1 (de) Verfahren zur modulation der tubulindeacetylase-aktivität
ATE506059T1 (de) Therapie zur behandlung der überaktiven blase
ATE217197T1 (de) Verwendung von hyaluronsäure und eines nsaid zur herstellung eines arzneimittels zur behandlung von krankheiten der mucosa
UA35567C2 (uk) Фармацевтичний препарат для лікування хворих з порушеннями функції коагуляції, спосіб лікування таких хворих, спосіб одержання фармацевтичного препарату
DK0758241T3 (da) Anvendelse af visse methanbisphosphonsyrederivater til at hindre løsning og vandring af proteser
WO2004039325A3 (en) Treatment of pain with jnk inhibitors
Hu et al. Dehydrocostus lactone attenuates osteoclastogenesis and osteoclast‐induced bone loss by modulating NF‐κB signalling pathway
DE59606784D1 (de) Verwendung von boswelliasäure und ihren derivaten zur hemmung der normalen und gesteigerten leukozytenelastase- oder plasminaktivität
RU2012108635A (ru) Ртн-содержащий терапевтический/профилактический агент против остеопороза, характеризующийся тем, что ртн вводят один раз в неделю в стандартной дозе 100-200 единиц
ATE350032T1 (de) Verwendung der protein-kinase-c-epsilon- inhibitoren zur behandlung von schmerzen
TW200616644A (en) Medicine for prevention or treatment of diabetes
Viana et al. Use of calcitonin in recalcitrant phantom limb pain complicated by heterotopic ossification
TW200503666A (en) Treatment of type 1 diabetes with pde5 inhibitors
ATE297732T1 (de) Kombinationstherapie zur behandlung von herzinsuffizienz
DE60108130D1 (de) Pharmazeutische zusammensetzungen zur behandlung von neurologischen krankheiten
PT1231908E (pt) Composicao farmaceutica compreendendo um composto dador de no e sua utilizacao em terapia
DE60306503D1 (de) Statin-therapie zur verbesserung der aufrechterhaltung der kognitiven funktion

Legal Events

Date Code Title Description
8364 No opposition during term of opposition